California-based cancer startup Dantari announced a $47 million Series A financing Thursday in its push to develop antibody-drug conjugates with its own spin on the treatments.
The company’s main candidate is called DAN-222, and it’s being evaluated in a Phase I/II clinical trial for the treatment of metastatic human epidermal...
